Clinton Seeks $220 Million for Poor Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 4
Volume 9
Issue 4

WASHINGTON-President Clinton has proposed spending $220 million over 5 years to pay for the treatment of women diagnosed in the federally supported National Breast and Cervical Cancer Early Detection Program.

WASHINGTON—President Clinton has proposed spending $220 million over 5 years to pay for the treatment of women diagnosed in the federally supported National Breast and Cervical Cancer Early Detection Program.

Mr. Clinton included the money in his proposed budget for fiscal year 2001 and urged Congress to enact the legislation necessary to create a new Medicaid option that would enable states to provide low-income, uninsured women with treatment for breast and cervical cancer.

The early breast and cervical cancer detection program now covers 360,000 women nationwide. However, once a diagnosis is made, there is no formal program to ensure a woman will receive prompt, comprehensive treatment, although federally sponsored screening programs try to obtain some therapy for such patients.

“Too often, uninsured women face a patchwork of care, inadequate care, or no care at all,” Mr. Clinton said in one of his weekly radio addresses, in which he announced the initiative. “Many are denied new or better forms of treatment, or wait months to see a doctor.”

According to a White House statement, “women who are uninsured are 40% more likely to die from breast cancer than those with insurance.” Finding treatment for these women diverts scarce resources from screening activities.

The proposed new Medicaid option would enable states, if they choose, to:

Provide the full Medicaid benefit package to low-income, uninsured women diagnosed with breast and cervical cancer through the federal detection program.

Ensure access to treatment without delay. “States would also have the option to allow health care providers and other qualified entities to provide critical health care services to women pending official enrollment in Medicaid,” the White House statement said.

Increase the amount actually spent on breast and cervical cancer screening. Some states currently supplement the federal funds they receive with state money for the treatment of the two diseases.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content